The management of univestigated dyspepsia in primary care

Minerva Gastroenterologica e Dietologica

Volumn 51, Issue 3, 2005, Pages 213-224

  Thijs, J C ^a   Kleibeuker, J H ^b  

^a Bethesda Hospital   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Dyspepsia; Helicobacter pylori; Patient management; Test and treat

Indexed keywords

PROTON PUMP INHIBITOR; STOMACH SECRETION INHIBITOR;

ABDOMINAL PAIN; CHRONIC DISEASE; DYSPEPSIA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GASTROSCOPY; HELICOBACTER PYLORI; HUMAN; PEPTIC ULCER; PHYSICIAN; PREVALENCE; PRIMARY MEDICAL CARE; RECURRENT DISEASE; REVIEW; SYMPTOM; UREA BREATH TEST;

DYSPEPSIA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PRIMARY HEALTH CARE;

EID: 28444447109     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999;45 Suppl 2:1137-1142.
2. Veldhuyzen van Zanten SJ, Flook N, Chiba N, Armstrong D, Barkun A, Bradette M et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. CMAJ 2000;102 Suppl 12:S3-23.
3. Jones R, Lydeard S. Prevalence of symptoms of dyspepsia in the community. Br Med J 1989;298:30-2.
4. Talley NJ Zinsmeister AR, Schleck CD, Melton LJ. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992;102:1259-68.
5. Klauser AG, Schindbeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 1990;335:205-8.
6. El-Serag HB, Talley NJ. Systematic review: the prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther 2004;19:643-54.
7. Talley NJ. Dyspepsia management in the millennium: the death of test and treat? Gastroenterology 2002;122:1521-5.
8. Eisen GM and the Standards of practice committee. The role of endoscopy in dyspepsia. Gastrointest Endosc 2001;54:815-7.
9. Lam SK, Talley Report of the 1997 Asia pacific consensus conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1997;13:1-12.
10. Ofman JJ, Rabeneck L. The effectiveness of endoscopy in the management of dyspepsia: a qualitative systematic review. Am J Med 1999;106:335-46.
11. American College of Physicians. Endoscopy in the Evaluation of Dyspepsia. Ann Intern Med 1985;102:266-9.
12. Chiba N, Bernard L, O'Brien BJ, Goeree R, Hunt RH. Canadian physician survey of dyspepsia management. Can J Gastroenterol 1998;12:83-90.
13. Numans ME, de Wit NJ, Dirven JAM, Hurenkamp GJB, Meyer ZCM, Muris JWM et al. NHG-standaard maagklachten (tweede herziening). Huisarts en Wetenschap 2003;46:690-700.
14. Arents NLA, Thijs JC, Kleibeuker JH. A rational approach to uninvestigated dyspepsia in primary care. Review of the Literature. Postgrad Med J 2002;78:707-16.
15. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004;127:1239-55.
16. Christie J, Sheperd NA, Codling BW, Valori RM. Gastric cancer below the age of 55: implications for screening patients with uncomplicated dyspepsia. Gut 1997;41:513-7.
17. Gillen D, McColl K E. Does concern about missing malignancy justify endoscopy in uncomplicated dyspepsia in patients aged less than 55? Am J Gastroenterol 1999;94:75-9.
18. Breslin NP, Thomson AB, Bailey RJ, Blustein PK, Meddings J, Lalor E et al. Gastric cancer and other endoscopic diagnoses in patients with benign dyspepsia. Gut 2000;46:93-7.
19. Canga C, Vakil N. Upper GI malignancy, uncomplicated dyspepsia, and the threshold for early endoscopy. Am J Gastroenterol 2002;97:600-3.
20. Lieberman D, Fennerty MB, Morris CD, Holub J, Eisen G, Sonnenberg A. Endoscopic evaluation of patients with dyspepsia: Results from the national endoscopic data repository. Gastroenterology 2004;127:1067-75.
21. Kagevi I, Lofstedt S, Persson L G. Endoscopic findings and diagnoses in unselected dyspeptic paptients at a primary health care center. Scand J Gastroenterol 1989;24:145-50.
22. Heikinnen M, Pikkarainen P, Takala J, Rasanen H, Julkunen R. Etiology of dyspepsia: four hundred unselected consecutive patients in general practice. Scand J Gastroenterol 1995;30:519-23.
23. Hansen JM. Dyspepsia in primary care. Clinical decision making and pharmacotherapy in non-organic dyspepsia. Odense, Danmark: Thesis, Odense University, 1995.
24. Thomson AB, Barkun AN, Armstrong D, Chiba N, White RJ, Daniels S et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003;17:1481-91.
25. El-Seraq H B, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1997;43:327-33.
26. Blaser M J. Helicobacter pylori and gastric diseases. Br Med J 1998;316:1507-10.
27. Holtmann G. Reflux disease: the disorder of the third millennium. Eur J Gastroenterol Hepatol 2001;13 Suppl 1:S5-11.
28. Laheij RJ, de Koning RW, Horrevorts AM, Rongen RJ, Rossum LG, Witteman EM et al. Predominant symptom behavior in patients with persistent dyspepsia during treatment. J Clin Gastroenterol 2004;38:490-5.
29. Graham DY, Colon-Pagan J, Morse RS, Johnson TL, Walsh JH, McCullough AJ et al. Ulcer recurrence following duodenal ulcer healing with omeprazole, ranitidine, or placebo: a double-blind, multicenter, 6-month study. The Omeprazole Duodenal Ulcer Study Group. Gastroenterology 1992;102:1289-94.
30. Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95:903-12.
31. Jones R, Lydeard S. Dyspepsia in the community: a follow-up study. Br J Clin Pract 1992;46:95-7.
32. Talley NJ. Drug treatment of functional dyspepsia. Scand J Gastroenterol 1991;182:47-60.
33. Moayyedi P, Delaney BC, Vakil N, Forman D, Talley NJ. The efficacy of proton pump inhibittors in non-ulcer dyspepsia. A systematic review and economic analysis. Gastroenterology 2004;127:1329-37.
34. Bytzer P, Hansen JM, Schaffalitzky de Muckadell OB. Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet 1994;343:811-6.
35. Griffin SM, Raimes SA. Proton pump inhibitors may mask early gastric cancer. Dyspeptic patients over 45 should undergo endoscopy before these drugs are started. BMJ 1998;317:1606-7.
36. Unge P, Jonsson B, Stalhammar NO. The cost effectiveness of Helicobacter pylori eradication versus maintenance and episodic treatment in duodenal ulcer patients in Sweden. Pharmacoeconomics 1995;8:410-27.
37. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004;99:1833-55.
38. Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Dominguez-Munoz JE. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database of Syst Rev 2004; CD004062.
39. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Hanu N, Festen HP et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334:1018-22.
40. Klinkenberg-Knol EC, Nelis, F, Dent J, Snel P, Mitchell B, Prichard P et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000;118:61-9.
41. rd et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92:118-24.
42. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;119:333-8.
43. Toruner M, Soykan I, Ensari A, Kuzu I, Yurdaydin C, Ozden A. Barrett's esophagus: prevalence and its relationship with dyspeptic symptoms. J Gastroenterol Hepatol 2004;19:535-40.
44. Connor MJ, Weston AP, Mayo MS, Sharma P. The prevalence of Barrett's esophagus and erosive esophagitis in patients undergoing upper endoscopy for dyspepsia in a VA population. Dig Dis Sci 2004;49:920-4.
45. Craanen ME, Blok P, Meijer GA, Meuwissen SG. Surveillance in Barrett's oesophagus: a critical reappraisal. Scand J Gastroenterol Suppl 2002;236:4-8.
46. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003;138:176-86.
47. Warren JR, Marshall BJ. Unidentified curved bacillus on the gastric epithelium in active chronic gastritis. Lancet 1983;1:1273-5.
48. Kuipers EJ, Thijs JC, Festen HPM. Helicobacter pylori and peptic ulcer disease. Aliment Pharmacol Ther 1995;9 Suppl 2:59-69.
49. Nomura A, Stemmermann G N, Chyou P H, Perez-Perez G I, Blaser M J. Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med 1994;120:977-81.
50. Sipponen P, Varis K, Fraki O, Korri U M, Seppala K, Siurala M. Cumulative 10 year risk of symptomatic duodenal and gastric ulcer disease in patients with or without chronic gastritis. Scand J Gastroenterol 1990;25:966-73.
51. Ciociola AA, McSorley DJ, Turner K, Sykes D, Palmer JBD. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol 1999;94:1834-40.
52. Arents NL, Thijs JC, van Zwet AA, Kleibeuker JH. Does the declining prevalence of Helicobacter pylori unmask patients with idiopathic peptic ulcer disease? Trends over an 8 year period. Eur J Gastroenterol Hepatol 2004;16:779-83.
53. Higuchi K, Arakawa T, Fuijwara Y, Uchida T, Tominaga K, Watanabe T et al. Is Helicobacter pylori-negative duodenal ulcer masked by the high prevalence of H.pylori infection in the general population? Am J Gastroenterol 1999;94:3083-4.
54. Danesh J, Lawrence M, Murphy M, Roberts S, Collins R. Systematic review of the epidemiological evidence on Helicobacter pylori infection and nonulcer or uninvestigated dyspepsia. Arch Intern Med 2000;160:1192-8.
55. Sarnelli G, Cuomo R, Janssens J, Tack J. Symptom patterns and pathophysiological mechanisms in dyspeptic patients with and without Helicobacter pylori. Dig Dis Sci 2003;48:2229-36.
56. Talley N J, Vakil N, Ballard E D, Fennerty M B. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med 1999;341:1106-11.
57. Talley N J, Janssens J, Lauritsen K, Racz I, Bolling-Sternevald E. Eradication of Helicobacter pylori in functional dyspepsia: randomized double-blind placebo controlled longterm trial with 12 months' follow-up. The Optimal Regimen Cures Helicobacter induced Dyspepsia (ORCHID) study group. BMJ 1999;318:833-7.
58. McColl K, Murray L, El-Omar E, Dickson A, El-Nujumi, Wirz A et al. Symptomatic benefit from eradicting Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998;339:1869-74.
59. Blum A L, Talley N J, O'Morain C, van Zanten SV, Labenz J, Stolte M et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med 1998;339:1875-81.
60. Moayyedi P, Soo S, Deeks J, Forman D, Mason J, Innes M, Delaney B. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Br Med J 2000;321:659-64.
61. Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001;134:361-9.
62. Moayyedi P, Decks J, Talley NJ, Delaney B, Forman D. An update of the Cochrane systematic review of Helicobacter eradication therapy in non-ulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003;98:2621-6.
63. Werdmuller BF, Loffeld RJ. Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis. Dig Dis Sci 1997;42:103-5.
64. O'Connor HJ. Review article: Helicobacter pylori and gastro-oesophageal reflux disease - clinical implications and management. Aliment Pharmacol Ther 1999;13:117-27.
65. Cremonini F, Di Caro S, Delgado-Aros S, Sepulveda A, Gasbarrini G, Gasbarrini A et al. Meta-analysis: the relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003;18:279-89.
66. Raghunath A, Hungin S, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastrooesophageal reflux disease: systematic review. BMJ 2003;326:737.
67. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997;112:1442-7.
68. McColl KE, Dickson A, El-Nujumi A, El-Omar E, Kelman A. Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. Am J Gastroenterol 2000;95:101-5.
69. Vakil N, Hahn B, McSorley D. Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:45-51.
70. Murai T, Miwa H, Ohkura R, Iwazaki R, Nagahara A, Sato K et al. The incidence of reflux oesophagitis after cure of Helicobacter pylori in a Japanese population. Aliment Pharmacol Ther 2000;14 Suppl 1:161-5.
71. Malfertheiner P, Dent J, Zeijlon L, Sipponen P, Veldhuyzen Van Zanten SJ et al. Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease. Rresults from a randomized trial programme. Aliment Pharmacol Ther 2002;16:1431-42.
72. Tefera S, Hatlebakk JG, Berstad A. Eradication of Helicobacter pylori does not increase acid reflux in patients with mild to moderate reflux oesophagitis. Scand J Gastroenterol 2002;37:877-83.
73. Harvey RF, Lane JA, Murray LJ, Harvey IM, Donovan JL, Nair P. Bristol Helicobacter Project. Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastrooesophageal reflux: Bristol helicobacter project. BMJ 2004;328:1417.
74. EUROGAST study group. An international association between Helicobacter pylori infection and gastric cancer. Lancet 1993;341:1359-62.
75. Uemura N, Okamoto S, Yamamoto S, Matsamura N, Yamaguchi S, Yamakido M et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
76. Kahl BS. Update: gastric MALT lymphoma. Curr Opin Oncol 2003;15:347-52.
77. Wu JC, Chan FK, Ching JY, Leung WK, Hui Y, Leong R et al. Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial. Gut 2004;53:174-9.
78. Koike T, Ohara S, Sekine H, Iijima K, Kato K, Toyota T et al. Increased gastric acid secretion after Helicobacter pylori eradication may be a factor for developing reflux oesophagitis. Aliment Pharmacol Ther 2001;15:813-20.
79. Verdu EF, Armstrong D, Idstrom JP, Labenz J, Stolte M, Dorta G et al. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 1995;37:738-43.
80. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon T. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001;121:1120-6.
81. Ishiki K, Mizuno M, Take S, Nagahara Y, Yoshida T, Yamamoto K et al. Helicobacter pylori eradication improves pre-existing reflux esophagitis in patients with duodenal ulcer disease. Clin Gastroenterol Hepatol 2004;2:474-9.
82. Schenk B E, Kuipers EJ, Klinkenberg-Knol EC, Eskes SA, Meuwissen SG. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol 1999;94:884-7.
83. Vakil NB, Traxler BM, Levine D. Symptom response and healing of erosive esophagitis with proton-pump inhibitors in patients with Helicobacter pylori infection. Am J Gastroenterol 2004;99:1437-41.
84. Sobala GM, Crabtree JE, Pentith JA, Rathbone BJ, Shallcross TM et al. Screening dyspepsia by serology to Helicobacter pylori. Lancet 1991;338:94-6.
85. Tham TC, McLaughlin N, Hughes DF, Ferguson M, Crosbie JJ, Madden M et al. Possible role of Helicobacter pylori serology in reducing endoscopy workload. Postgrad Med J 1994;70:809-12.
86. Patel P, Khulusi S, Mendall MA, Lloyd R, Jazrawi R, Maxwell JD et al. Prospective screening of dyspeptic patients by Helicobacter pylori serology. Lancet 1995;346:1315-8.
87. Delaney BC, Wilson S, Roalfe A, Roberts L, Redman V, Wearn A et al. Randomised controlled trial of Helicobacter pylori testing and endoscopy for dyspepsia in primary care. BMJ 2001;322:898-901.
88. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A et al. European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
89. Talley NJ, Siverstein MD, Agreus L, Nyren O, Sonnenberg A, Holtman G. AGA technical review: evaluation of dyspepsia. American Gastroenterological Association. Gastroenterology 1998;114:582-95.
90. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998;13:1-12.
91. Talley NJ, Axon A, Bytzer P, Holtman G, Lam SK, Van Zanten S. Management of uninvestigated and functional dyspepsia: a Working Party report for the World Congresses of Gastroenterology 1998. Aliment Pharmacol Ther 1999;13:1-12.
92. Hunt R, Fallone C, Veldhuyzan van Zanten S, Sherman P, Smaill F, Flook N et al. CHSG 2004 participants. Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori-an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H. pylori infection. Can J Gastroenterol 2004;18:547-54.
93. Fendrick AM, Chernew ME, Hirth RA, Bloom BS. Alternative management strategies for patients with suspected peptic ulcer disease. Ann Intern Med 1995;123:260-8.
94. Silverstein MD, Petterson T, Talley NJ. Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterology 1996;110:72-83.
95. Briggs AH, Sculpher MJ, Logan RP, Aldous J, Ramsay ME, Baron JH. Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age. Br Med J 1996;312:1321-5.
96. Ofman JJ, Etchason J, Fullerton S, Kahn KL, Soll AH. Management strategies for Helicobacter pylori - seropositive patients with dyspepsia: clinical and economic consequences. Ann Intern Med 1997;126:280-91.
97. Spiegel BMR, Vakil NB, Ofman JJ. Dyspepsia management strategies: a decision analysis of competing strategies. Gastroenterology 2002;122:1270-85.
98. Moayyedi P. Helicobacter pylori test and treat strategy for young dyspeptic patients: new data. Gut 2002;50 Suppl 4:47-50.
99. Lassen AT, Pedersen FM, Bytzer P, Schaffalitzky de Muckadell OB. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial. Lancet 2000;356:455-60.
100. Lassen AT, Hallas J, Schaffalitzky de Muckadell OB. Helicobacter pylori test and eradicate versus prompt endoscopy for management of dyspeptic patients: 6.7 year follow-up of a randomised trial. Gut 2004;53:1758-63.
101. McColl KEL, Murray LS, Gillen D, Walker A, Wirz A, Fletcher J et al. Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H. pylori testing alone in the management of dyspepsia. BMJ 2002;324:999-1002.
102. Arents NLA, Thijs JC, Zwet van AA, Oudkerk Pool M, Götz JM, Van de Werf GTh et al. The approach of dyspepsia in primary care. A randomised trial comparing "test-and-treat" with prompt endoscopy. Arch Intern Med 2003;163:1606-12.
103. Heaney A, Collins JSA, Watson RGP, McFarland RJ, Bamford KB, Tham TCK. A prospective randomised trial of a test-and-treat policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic. Gut 1999;45:186-90.
104. Jones R, Tait C, Sladen G, Weston-Baker J. A trial of a test-and-treat strategy for Helicobacter pylori positive dyspeptic patients in general practice. Int J Clin Pract 1999;53:413-6.
105. Manes G, Menchise A, de Nucci C, Balzano A. Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment. BMJ 2003;326:1118.
106. Gisbert JP, Badia X, Roset M, Pajares JM. The TETRA study: a prospective evaluation of Helicobacter pylori "test-and-treat" strategy on 736 patients in clinical practice. Helicobacter 2004;9:28-38.
107. Gisbert JP, Badia X, Roset M, Pajares JM., Guth A, Malfertheiner P et al. Efficacy of Helicobacter pylori eradication in uninvestigated chronic dyspeptic staff members of a large factory: a prospective, long-term, follow-up, workplace outcome study. Eur J Gastroenterol Hepatol 2002;14:61-9.
108. Bowie PE, Cox RA, Davidson AR, Steel A. Young dyspeptic patients: with a test-and-treat policy, are the benefits of decreased symptom severity and oesophago-gastric-duodenoscopy workload sustained? Eur J Gastroenterol Hepatol 2001;13:541-5.
109. Farkkila M, Sarna S, Valtonen V, Sipponen P; PROSPER Study Group. Does the "test-and-treat" strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two-year follow-up study of 1 552 patients. Scand J Gastroenterol 2004;39:327-35.
110. Correa P. Is gastric cancer preventable? Gut 2004;53:1217-9.
111. Thijs JC, van Zwet AA, Moolenaar W, Wolfhagen MJ, ten Bokkel HJ. Triple therapy vs amoxicillin plus omeprazole for treatment of Helicobacter pylori infection: a multicenter, prospective, randomized, controlled study of efficacy and side effects. Am J Gastroenterol 1996;91:93-7.
112. De Boer WA, Tytgat GN. The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice? Scand J Gastroenterol 1995;30:401-7.
113. Van der Wouden EJ, Thijs JC, van Zwet AA, Sluiter WJ, Kleibeuker JH. The influence of in vitro nitroimidazole resistance on the efficacy of nitromidazole containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 1999;94:1751-9.
114. Houben MH, van der Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicobial resistance on eradication rates Aliment Pharmacol Ther 1999;13:1047-55.
115. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-84.
116. Arents NLA, van Zwet AA, Thijs JC, Degener JE, Kleibeuker JH. A six-year surveillance of Helicobacter pylori resistance in a large study population in the Netherlands (n=5 946): prevalence of clarithromycin resistance increases, while metronidazole resistance does not increase. Gastroenterology 2001;120:A229.
117. De Boer WA. How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. A personal viewpoint. J Clin Gastroenterol 1996;22:313-16.
118. Thijs JC, van Zwet AA, Thijs WJ, Oey HB, Karrenbeld A, Stellaard F et al. Diagnostic tests for Helicobacter pylori: a prospective evaluation of their accuracy, without selecting a single test as the gold standard. Am J Gastroenterol 1996;91:2125-9.
119. Arents NLA, van Zwet AA, Thijs JC, de Jong A, Oudkerk-Pool M, Kleibeuker JH. The accuracy of the Helicobacter pylori antigen stool test in diagnosisng H. pylori in treated and untreated patients. Eur J Gastroenterol Hepatol 2001;13:383-6.
120. Gisbert JP, Pajares JM. Stool antigen test for the diagnosis of Helicobacter pylori infection: a systematic review. Helicobacter 2004;9:347-68.
121. Moayyedi P, Axon AT. The usefulness of the likelihood ratio in the diagnosis of dyspepsia and gastroesophageal reflux disease. Am J Gastroenterol 1999;94:3122-5.
122. Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ, Klain PD et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroentero-logy 1992;102:493-6.
123. Bytzer P. Diagnostic approach to dyspepsia. Best Pract Res Clin Gastroenterol 2004;18:681-93.